Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.

Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill

Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen, will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m.

Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices

U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,000 a month.

Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing

Amgen

Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.

2 Weight-Loss Stocks That Could Rocket Higher This Year

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.

Novo says Ozempic to be eligible for US price negotiations in less than a year

Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss drugs Wegovy and Ozempic.

Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices

Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S NVO, is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company's diabetes and weight-loss drugs, including Ozempic and Wegovy.

Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday

Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.

NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.

Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports

The latest news from the Danish drug developer was not encouraging. Its experimental weight loss drug produced results, but also a set of side effects.

Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today

Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm's latest obesity treatment showed less effectiveness in higher doses.

Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.

NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.

Novo Nordisk shares drop more than 4% on disappointing obesity pill data

Corbus Pharmaceuticals Holdings

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects

The blockbuster drug strengthens its case that obesity drugs have health benefits beyond weight-loss.

Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.

EU regulator backs use of Novo's Wegovy for obesity-related heart condition

Wegovy ® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Supply constraints for the obesity business are easing, and we should see growth pick up in the second half of the year and more so in 2025. Oral amycretin candidate data look good, with no new safety and tolerability signals.

Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential

Novo Nordisk and Korro Bio just signed a big collaboration deal. The pair aim to develop medicines involving mRNA, which is Moderna's specialty.

Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may be rising significantly. Medicare and Medicaid are covering a significant number of the prescriptions of these drugs, with Medicaid covering Wegovy in 20 states.

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership combines NanoVation Therapeutics' proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liver.

NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive.

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports

DexCom

Novo Nordisk is the leader in developing drugs in a fast-growing area. DexCom's recent drop doesn't take away from its long runway for growth.

News for Novo Nordisk Stock (NVO)